International audienceIntermittent preventive treatment in pregnancy with sulfadoxine and pyrimethamine (IPTp-SP) is a key component in the malaria control strategy implemented in Africa. The aim of this study was to determine IPTp-SP adherence and coverage, and the impact on maternal infection and birth outcomes in the context of widespread SP resistance in the city of Douala, Cameroon. Clinical and demographic information were documented among 888 pregnant women attending 3 health facilities, from the antenatal care visit to delivery. Positive samples were genotyped for P. falciparum gene (dhfr, dhps, and k13) mutations. The overall IPTp-SP coverage (≥three doses) was 17.5%, and 5.1% received no dose. P. falciparum prevalence was 16%, wit...
BackgroundThe effectiveness of sulphadoxine-pyrimethamine (SP) intermittent preventive treatment of ...
Abstract Background Pregnant women are a high-risk group for Plasmodium falciparum infections, which...
Objectives: To determine, 6 years after the adoption of intermittent preventive treatment of pregnan...
International audienceIntermittent preventive treatment in pregnancy with sulfadoxine and pyrimetham...
International audienceIntermittent preventive treatment in pregnancy with sulfadoxine and pyrimetham...
International audienceIntermittent preventive treatment in pregnancy with sulfadoxine and pyrimetham...
Background Increasing resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) threaten...
Background: Increasing resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) threate...
Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent preventiv...
Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent preventiv...
Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent preventiv...
Background: Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, mo...
Background Plasmodium falciparum resistance to sulphadoxine-pyrimethamine (SP) threatens the efficac...
Background: Pregnant women are a high-risk group for Plasmodium falciparum infections, which may res...
Intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) is used ...
BackgroundThe effectiveness of sulphadoxine-pyrimethamine (SP) intermittent preventive treatment of ...
Abstract Background Pregnant women are a high-risk group for Plasmodium falciparum infections, which...
Objectives: To determine, 6 years after the adoption of intermittent preventive treatment of pregnan...
International audienceIntermittent preventive treatment in pregnancy with sulfadoxine and pyrimetham...
International audienceIntermittent preventive treatment in pregnancy with sulfadoxine and pyrimetham...
International audienceIntermittent preventive treatment in pregnancy with sulfadoxine and pyrimetham...
Background Increasing resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) threaten...
Background: Increasing resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) threate...
Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent preventiv...
Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent preventiv...
Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent preventiv...
Background: Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, mo...
Background Plasmodium falciparum resistance to sulphadoxine-pyrimethamine (SP) threatens the efficac...
Background: Pregnant women are a high-risk group for Plasmodium falciparum infections, which may res...
Intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) is used ...
BackgroundThe effectiveness of sulphadoxine-pyrimethamine (SP) intermittent preventive treatment of ...
Abstract Background Pregnant women are a high-risk group for Plasmodium falciparum infections, which...
Objectives: To determine, 6 years after the adoption of intermittent preventive treatment of pregnan...